Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      OxyContin maker Purdue Pharma gets court approval for covering plaintiffs fees

      OxyContin maker Purdue Pharma gets court approval for covering plaintiffs fees

      Medical Dialogues Bureau20 Nov 2019 9:00 AM IST
      OxyContin maker Purdue proposed a $200 million emergency fund last month that could be spent quickly on addiction treatment while the parties resolve...
      USFDA pulls up Mylan for manufacturing violations at Andhra plant

      USFDA pulls up Mylan for manufacturing violations at Andhra plant

      Medical Dialogues Bureau19 Nov 2019 4:40 PM IST
      New Delhi: American health regulator USFDA has pulled up Mylan Laboratories for violation of good manufacturing norms, including lapses in handling...
      Novartis shifts Shanghais focus from research to early development

      Novartis shifts Shanghai's focus from research to early development

      Medical Dialogues Bureau19 Nov 2019 12:53 PM IST
      ZURICH: Novartis is halting early-stage research in Shanghai and shifting the site's focus to commercial development three years after the Swiss...
      USFDA lens slow down Indian pharma exports, says CII official

      USFDA lens slow down Indian pharma exports, says CII official

      Medical Dialogues Bureau19 Nov 2019 12:44 PM IST
      Hyderabad: Frequent inspections of Indian plants by the US FDA and subsequent observations slow down the growth of pharma exports even as US-China...
      NCLAT rejects Dhanuka Labs Rs 1146 crore bid for Orchid Pharma for being less than Liquidation Value

      NCLAT rejects Dhanuka Labs Rs 1146 crore bid for Orchid Pharma for being less than Liquidation Value

      Medical Dialogues Bureau19 Nov 2019 12:36 PM IST
      New Delhi: The NCLAT has rejected the bid of Dhanuka Laboratories for the debt ridden Orchid Pharma, and vacated the order passed by the Chennai-bench...
      Bristol Myers Squibb gets FTC okay for acquiring Celgene

      Bristol Myers Squibb gets FTC okay for acquiring Celgene

      Medical Dialogues Bureau18 Nov 2019 9:50 AM IST
      "The Commission has ordered Bristol Myers Squibb to divest Otezla to preserve BMS's incentive to continue developing its own oral product for treating...
      Novartis sets out new strategy to provide medicines to more patients in sub-Saharan Africa

      Novartis sets out new strategy to provide medicines to more patients in sub-Saharan Africa

      Medical Dialogues Bureau18 Nov 2019 9:00 AM IST
      New Delhi: Novartis announced recently a new strategy to broaden patient reach and availability of its portfolio of medicines in sub-Saharan Africa...
      Mylan Andhra plant gets USFDA warning over Valsartan manufacturing violations

      Mylan Andhra plant gets USFDA warning over Valsartan manufacturing violations

      Medical Dialogues Bureau17 Nov 2019 10:15 AM IST
      The concerns cited by the agency were based on an inspection conducted from May 27, 2019, to June 5, 2019, which placed a primary focus on the...
      Novartis forecast USFDA approved sickle-cell drug Adakveo annual sales to top USD 1 billion

      Novartis forecast USFDA approved sickle-cell drug Adakveo annual sales to top USD 1 billion

      Medical Dialogues Bureau17 Nov 2019 10:00 AM IST
      Novartis has forecast that the drug's (Adakveo) annual sales will top $1 billion, much of which will likely come from U.S. government payers such as...
      Divis Labs gets no USFDA observations for Unit-I Telangana facility

      Divis Labs gets no USFDA observations for Unit-I Telangana facility

      Medical Dialogues Bureau17 Nov 2019 9:45 AM IST
      "This is to inform that the Company's Unit-I facility at Lingojigudem, Bhuvanagiri Yadadri District, Telangana has been inspected by the USFDA,"...
      Agile birth control patch Twirla USFDA review delayed by 3 months, shares slide

      Agile birth control patch Twirla USFDA review delayed by 3 months, shares slide

      Medical Dialogues Bureau17 Nov 2019 9:25 AM IST
      Twirla, a once-weekly contraceptive patch made from a combination of hormones Ethinyl estradiol and levonorgestrel, was backed by a panel of...
      BeiGene gets USFDA approval for lymphoma drug Brukinsa

      BeiGene gets USFDA approval for lymphoma drug Brukinsa

      Medical Dialogues Bureau17 Nov 2019 9:20 AM IST
      BeiGene tested the treatment, Brukinsa, in 118 patients with mantle cell lymphoma enrolled in two studies. About three-quarters were Asian, 21%...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok